In this study we have explored the efficacy of NKT-01 in treating acute rejection episodes in dogs receiving renal allografts.
Unrelated outbred beagle dogs were used for the experiment.
Renal allografting was performed as previously described.8»9) Briefly, grafted kidneys were placed in the iliac fossa with end-to-end anastomosis of the renal artery to the external iliac artery and end-to-side anastomosis of the renal vein to the external iliac vein, and implantation of the ureter into the base of the urinary bladder. Plasma creatinine (p-Cr) and blood urea nitrogen (BUN) tests were performed after the operation until the animal died. NKT-01 was supplied from Takara Shuzo Co., Ltd., Kyoto.105 It was dissolved in saline and administered intravenously from the day of acute rejection onset. Details of the administered dose and schedule are shown in Fig. 2 . A control group of dogs received no treatment after the operation. Onset of rejection was defined as acute rise of p-Cr. BUN levels and clinical signs such as heat up of the abdominal transplantation site and an increase in water consumption were also considered to diagnose the onset of rejection. Dead or moribund-sacrificed animals were subjected to macroscopic and microscopic examinations. a) From the day of rejection onset, NKT-01was administered intravenously as a rescue treatment for rejection at a dose of 4.8 mg/kg/day for the first two days, 2.4 mg/kg/day for the next two days and 1.2 mg/kg/day for the last three days, b) dosage of NKT-01, mg/kg, c, d) p-Cr levels in the morning and afternoon of 5th postoperative days, respectively, e) a rise of was due to the transient renal disfunction related to grafting, f) moribund sacrificed, g) sacrificed, h) died. disturbances due to immuneresponses were observed in the renal cortex together with cellular rejection features similar to the control group. Canine renal allotransplantation has been used for the preclinical evaluation of immunosuppressive agents.n'12) Efficacies of antilymphocyte globulin and methylprednisolone which have been used for treating acute rejection in clinics have been also confirmed in this experimental model.13'14) On the basis of these earlier findings, we evaluated the efficacy of NKT-01 in the treatment of acute renal allograft rejection in dogs, and found that NKT-01 clearly reversed the acute rejection episodes. The efficacy of NKT-01was also confirmed by histopathologic examinations. The experimental model used in this study has been reported to be a severe model for assessing the ability of drugs to reverse an acute rejection episode.13»15) Taking into consideration the severity of this dog model together with the favorable results in this study, we expect NKT-01to become a potent agent for treating acute rejection episodes in organ transplantation. In further studies, the efficacy of NKT-01should be evaluated in a modeanalogous to the clinical situation such as in combined treatments with corticosteroids, azathioprine or cyclosporin A.
